This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher (TMO) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Challenging macroeconomic conditions and slowdown in activities in China impede Thermo Fisher's (TMO) Q2 revenues.
Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the second quarter of 2023.
NextGen (NXGN) Q1 Earnings Top Estimates, Revenues Surge Y/Y
by Zacks Equity Research
NextGen's (NXGN) first-quarter fiscal 2024 results reflect strength in its revenue sources.
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
The Zacks Analyst Blog Highlights Alphabet, Procter & Gamble, Linde, Comcast and Elevance Health
by Zacks Equity Research
Alphabet, Procter & Gamble, Linde, Comcast and Elevance Health are included in this Analyst Blog.
Top Analyst Reports for Alphabet, Procter & Gamble & Linde
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), The Procter & Gamble Company (PG) and Linde plc (LIN).
Company News for Jul 20, 2023
by Zacks Equity Research
Companies In The News Are: MTB, ELV, BKR, NTRS.
Elevance Health (ELV) Beats on Q2 Earnings, Ups '23 Profit View
by Zacks Equity Research
Elevance Health's (ELV) Q2 results benefit from an expanding customer base and solid pharmacy product revenues. Adjusted net income is expected to be more than $32.85 per share for 2023.
Elevance Health (ELV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 2.49% and 4.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Carelon Growth Aid Elevance Health's (ELV) Q2 Earnings?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to reflect rising memberships in Medicare Advantage, Medicaid, Vision and Dental Administration businesses.
Elevance Health (ELV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Linde, Elevance Health, Lam Research, KLA and Johnson Controls
by Zacks Equity Research
Linde, Elevance Health, Lam Research, KLA and Johnson Controls are part of the Zacks top Analyst Blog.
Top Stock Reports for Linde, Elevance Health & Lam Research
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Elevance Health, Inc. (ELV) and Lam Research Corporation (LRCX).
DocGo Inc. (DCGO) Surges 5.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
DocGo Inc. (DCGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Top Stock Reports for Meta Platforms, Boeing & IBM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), The Boeing Company (BA) and International Business Machines Corporation (IBM).
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top Research Reports for Tesla, TotalEnergies & Intuitive Surgical
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), TotalEnergies SE (TTE) and Intuitive Surgical, Inc. (ISRG).
Why Elevance Health (ELV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Here's Why You Should Hold Elevance (ELV) in Your Portfolio
by Zacks Equity Research
Improving top line, investments in high-growth businesses, membership hikes and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
Why Is Elevance Health (ELV) Up 0% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View
by Zacks Equity Research
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.